These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33616606)

  • 1. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
    Meyers DE; Jenei K; Chisamore TM; Gyawali B
    JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
    Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
    Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.
    Li YYR; Mai H; Trudeau ME; Mittmann N; Chiasson K; Chan KKW; Cheung MC
    Curr Oncol; 2020 Oct; 27(5):e495-e500. PubMed ID: 33173389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
    Raymakers AJN; Regier DA; Peacock SJ
    Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
    Jenei K; Meyers DE
    BMJ Open; 2023 Oct; 13(10):e066378. PubMed ID: 37844982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
    Lexchin J
    BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
    Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
    Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of the Cancer Drug Funding Process in Canada.
    Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
    Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
    Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
    Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
    JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.
    Skedgel C; Wranik D; Hu M
    Pharmacoeconomics; 2018 Apr; 36(4):467-475. PubMed ID: 29353385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.
    Jenei K; Gentilini A; Haslam A; Prasad V
    Lancet Oncol; 2024 Aug; 25(8):979-988. PubMed ID: 39004098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada.
    Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D
    Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
    Parmar A; Jiao T; Saluja R; Chan KKW
    Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
    Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
    J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
    Lemieux J; Audet S
    Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?
    McDonald H; Charles C; Elit L; Gafni A
    Pharmacoeconomics; 2015 Mar; 33(3):235-41. PubMed ID: 25424496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value assessment of oncology drugs using a weighted criterion-based approach.
    Ezeife DA; Dionne F; Fares AF; Cusano ELR; Fazelzad R; Ng W; Husereau D; Ali F; Sit C; Stein B; Law JH; Le L; Ellis PM; Berry S; Peacock S; Mitton C; Earle CC; Chan KKW; Leighl NB
    Cancer; 2020 Apr; 126(7):1530-1540. PubMed ID: 31860138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of Anti-cancer Therapies with Reimbursement Limited to Comprehensive Cancer Centres Using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale].
    Büchler T; Melichar B; Vrána D; Lemstrová R; Fínek J; Dušek L; Petráková K; Prausová J
    Klin Onkol; 2017; 30(5):349-360. PubMed ID: 29031037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.